

# ISO 22679:2021-11 (E)

## Cardiovascular implants - Transcatheter cardiac occluders

---

<b>Contents</b>		<b>Page</b>
Foreword .....		v
Introduction .....		vi
1	Scope .....	1
2	Normative references .....	1
3	Terms and definitions .....	2
4	Abbreviations .....	6
5	Fundamental requirements .....	7
5.1	General .....	7
5.2	Risk management .....	7
6	Device description .....	8
6.1	General .....	8
6.2	Intended use .....	8
6.3	Design inputs .....	8
6.3.1	Operational principles and specifications .....	8
6.3.2	Functional, performance and safety requirements .....	8
6.3.3	Implant procedure: Device and usability requirements .....	9
6.3.4	Packaging, labelling and sterilization .....	10
6.4	Design outputs .....	10
6.5	Design transfer (manufacturing verification or validation) .....	10
7	Design verification and validation .....	10
7.1	General requirements .....	10
7.2	In vitro assessment .....	11
7.2.1	General .....	11
7.2.2	Test conditions, sample selection and reporting requirements .....	11
7.2.3	Material property assessment .....	12
7.2.4	Structural performance assessment .....	13
7.2.5	Component corrosion assessment .....	14
7.2.6	Visibility .....	14
7.2.7	Visual inspection .....	15
7.2.8	Dimensional verification .....	15
7.2.9	Device MRI compatibility .....	15
7.2.10	Simulated use assessment .....	15
7.2.11	Usability engineering process .....	15
7.2.12	Design- or procedure-specific testing .....	15
7.3	Preclinical in vivo evaluation .....	15
7.3.1	General .....	15
7.3.2	Overall requirements .....	15
7.3.3	Methods .....	17
7.3.4	Test report .....	18
7.4	Clinical investigations .....	19
7.4.1	General .....	19
7.4.2	Study considerations .....	20
7.4.3	Imaging assessment .....	21
7.4.4	Study design .....	21

7.4.5	Explant analysis .....	21
7.4.6	Pilot study considerations .....	22
7.4.7	Study endpoints .....	22
7.4.8	Ethical considerations .....	22
7.4.9	Pivotal studies: Distribution of subjects and investigators .....	23
7.4.10	Site qualification and training requirements .....	23
7.4.11	Study population .....	23
7.4.12	Statistical considerations .....	24
7.4.13	Sample size .....	25
7.4.14	Duration of study .....	25
7.4.15	Patient selection criteria .....	25
7.4.16	Clinical data requirements .....	26
Annex A (informative)	Rationale for the provisions of this document .....	31
Annex B (informative)	Transcatheter cardiac occluder hazard analysis example .....	34
Annex C (normative)	Packaging .....	36
Annex D (normative)	Product labels and instructions for use .....	37
Annex E (normative)	Sterilization .....	38
Annex F (informative)	Corrosion assessment .....	39
Annex G (informative)	In vitro test guidelines for paediatric devices .....	42
Annex H (informative)	Fatigue and durability assessment .....	44
Annex I (normative)	Adverse event classification during clinical investigation .....	50
Annex J (informative)	Imaging protocol .....	55
Annex K (informative)	Clinical investigation endpoints for transcatheter cardiac occluders: Suggestions for endpoints and their timing .....	56
Annex L (informative)	Examples of design specific testing .....	59
Annex M (informative)	Guidelines for delivery system design evaluation .....	61
Annex N (normative)	Preclinical in vivo evaluation .....	63
Annex O (informative)	In vitro test pressure guidelines .....	66
Annex P (informative)	Training for physicians and support staff .....	68
Bibliography	.....	69